EGFR and non-small cell lung carcinoma: The phase III ADAURA trial demonstrated that adjuvant osimertinib significantly improved disease‐free survival (DFS) and overall survival (OS) in patients with completely resected, EGFR‐mutated, stage IB to IIIA NSCLC [7].